Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumococcal vaccine response in lymph nodes
NL-OMON58614Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Leiden University Medical Center. Primary endpoint: Percentage of polysaccharide-specific germinal center B cells in lymph node aspirates. Started Apr 2023; status: recruiting.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON58614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58614.